Form 4 for CRH CRH plc
Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-03 · accession 0000950170-25-033680 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-05 | 2025-03-03 | CRH | Foley Isabel | Group GC | F - Tax | $95.23 | -20.2K | 52.5K | -28% | -$1.93M |
| D | 2025-03-05 | 2025-03-03 | CRH | Foley Isabel | Group GC | A - Grant | $0.00 | +32.5K | 68.9K | +89% | $0 |
| D | 2025-03-05 | 2025-03-03 | CRH | Foley Isabel | Group GC | M - OptEx | $0.00 | +3,867 | 72.8K | +6% | $0 |
| D | 2025-03-05 | 2025-03-03 | CRH | Foley Isabel | Group GC | M - OptEx | $0.00 | -3,543 | 7,394 | -32% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-03-03 | F | D | 20,242 | $95.23 | 52,530 | D | — | — | (F3) Mandatory sale of sufficient Ordinary Shares to cover applicable withholding tax liabilities arising in the connection with the aforementioned awards (F4) The reported price represents the volume-weighted average price of shares sold. Sale prices for the reported transaction ranged between $92.75 and $ 98.705 inclusive of shares sold on the New York Stock Exchange. Full information regarding the number of Ordinary Shares sold at each separate price in the range will be provided to the SEC upon request. |
| 2 | Common | Ordinary Shares | 2025-03-03 | A | A | 32,461 | $0.00 | 68,905 | D | — | — | (F1) Reflects the vesting and release of awards granted in 2022 under the 2014 Performance Share Plan Rules on March 3, 2025 (including the award of 2,717 additional Ordinary Shares as dividend equivalents), pursuant to certification of the achievement of pre-established performance goals by the Compensation Committee of the Board of Directors of the Issuer (the "Compensation Committee"). |
| 3 | Common | Ordinary Shares | 2025-03-03 | M | A | 3,867 | $0.00 | 72,772 | D | — | — | (F2) Reflects the vesting and release of a 2022 time-based conditional award as defined in the 2014 Deferred Share Bonus Plan (the "DSB Plan Rules"), of which, pursuant to the determination of the Compensation Committee, a total of 3,867 shares vested on March 3, 2025, including the award of 324 additional Ordinary Shares as dividend equivalents. Subject to the determination of the Compensation Committee, the remaining awards of 4,307 shares and 3,087 shares are expected to vest in March 2026 and March 2027, respectively. In accordance with the DSB Plan Rules, dividend equivalents will apply to these awards and, to the extent awarded, will be reported at the time of vesting. |
| 4 | Derivative | Deferred Share Award | 2025-03-03 | M | D | 3,543 | $0.00 | 7,394 | D | $0.00 · — to — | 3,543 Ordinary Shares | (F2) Reflects the vesting and release of a 2022 time-based conditional award as defined in the 2014 Deferred Share Bonus Plan (the "DSB Plan Rules"), of which, pursuant to the determination of the Compensation Committee, a total of 3,867 shares vested on March 3, 2025, including the award of 324 additional Ordinary Shares as dividend equivalents. Subject to the determination of the Compensation Committee, the remaining awards of 4,307 shares and 3,087 shares are expected to vest in March 2026 and March 2027, respectively. In accordance with the DSB Plan Rules, dividend equivalents will apply to these awards and, to the extent awarded, will be reported at the time of vesting. |